RESULTS	A single priming dose of either MF59-adjuvanted formulation was sufficient to meet the European licensure criteria for pandemic influenza vaccines ( HI titres 1:40 > 70 % ; seroconversion > 40 % ; and GMR > 2.5 ) .\